EMA delays Valneva vaccine approval
The approval of Valneva’s Corona vaccine is delaying. The European Medicines Agencys CHMP requested additional data.
Mimetas BV participating in 325m cancer funding
Organ-on-chip disease model specialist Mimentas BV participates in a 325m funding to accelerate preclinical cancer R&D in the Netherlands.
Hansa Biopharmas imlifidase advances to Phase III testing
The US Food & Drug Administration has given the green light for Phase III testing of Hansa Biopharmas imlifidase in anti-GBM disease.
GSK acquires Sierra Oncology for 1.9bn
GlaxoSmithKline acquires California-based Sierra Oncology and a ready-for-approval product candidate for myelofibrosis.
Scientists print 3D cancer model
A 3D tumour model developed by scientists enables drug screening in metastases
Affimed prices public offering to finance NK cell trials
Following phantastic AFM13 data at AACR, Affimed N.V. prices it public offering at $84.4m.
GeNeuro finds biologic against post-COVID syndrome
Swiss neurology specialist GeNeuro SA present first data linking silent COVID-19-induced inflammations to neuropsyciatric diseases.
Catalent swallows VMIC Ltd
Catalent has acquired a biologics manufacturing site from VMIC Ltd that is still under construction.
AXA launches 440 m private equity healthcare strategy
AXA IM Alts, has launched a Global Health Strategy following a 18m cornerstone commitment from AXA Group, as it builds on its existing offering in the sector.
Bayer Leaps to invests 1.3bn externally
German Bayer AG has announced it will channel at least 1.3b by the end of 2024 in its investment arm ‘Leaps by Bayer’.